Shuyu Zhang, PhD, Sichuan University, China
Jianping Cao, PhD, Soochow University, China
Xiaobo Du, PhD, University of Electronic Science and Technology of China, China
Image credit: © Mark Kostich / Getty Images / iStock
The ultra-high dose rate (UHDR) radiation shows promise in eradicating tumors while reducing normal tissue toxicities. However, the biological outcomes of UHDR are influenced by various factors, particularly t...
Hepatocellular carcinoma is one of the most common malignant tumors, and radiotherapy plays a pivotal role in its therapeutic regimen. However, radiotherapy resistance is the main cause of therapeutic failure ...
Partial stereotactic body radiation therapy (SBRT) targeting hypoxic regions of large tumors (SBRT-PATHY) has been shown to enhance the efficacy of tumor radiotherapy by harnessing the radiation-induced immune...
Radiation-induced intestinal injury (RIII) interrupts the scheduled processes of abdominal and pelvic radiotherapy (RT) and compromises the quality of life of cancer survivors. However, the specific regulators...
Radiation-induced skin injury (RISI) represents a significant complication in patients receiving radiotherapy and individuals exposed to nuclear accidents, characterized by a protracted wound-healing process r...
Ionizing radiation (IR), including radiotherapy, can exert lasting harm on living organisms. While liposaccharide (LPS) offers resistance to radiation damage, it also induces toxic responses. Thankfully, an LP...
Each year, millions of cancer patients undergo radiotherapy to treat malignant masses surrounded by non cancerous tissues or normal cell environments. Since its first application over 100 years ago, cancer radiotherapy continually evolves to enhance its precision with less side effects.
This Collection delves into the pivotal theme of " Novel Technologies in Radiotherapy". New technologies include physical, medical and biological advancement in radiotherapy.
From various aspects, this Collection explores the diverse strategies employed to augment the precision and safety of cancer radiotherapy at the molecular and cellular level. Moreover, benign diseases treated by radiotherapy are also taken into account.
This Collection welcomes submission of original research and review. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal.
Articles for this Collection should be submitted via our submission system, Snapp. Please, select the appropriate Collection title “Novel Technologies in Radiotherapy" under the “Details” tab during the submission stage.
Articles will undergo the journal’s standard peer-review process and are subject to all the journal’s standard policies. Articles will be added to the Collection as they are published.
The Editors have no competing interests with the submissions which they handle through the peer-review process. The peer-review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.